Company: INDP
Filing Date: 2025-02-12
Form Type: S-1
Source: 0001493152-25-006068
Chunk: 158

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-02-12
Form: S-1
Chunk 158
---
 research and development                |     |                                 |  17,309 |     |   |  80,910 |
| Other prepaid expenses                          |     |                                 |  61,750 |     |   | 120,315 |
| Total prepaid expenses and other current assets |     | $                               | 633,156 |     | $ | 811,433 |
| Prepaid expenses and other current assets       |     | $                               | 633,156 |     | $ | 811,433 |

NOTE 5: ACCOUNTS PAYABLE AND OTHER CURRENT LIABILITIES

Accounts payable and other current liabilities are comprised of the following:

SCHEDULE OF ACCOUNTS PAYABLE AND OTHER CURRENT LIABILITIES

|                                                      |     | For the year ended December 31, |      2023 |     |   |      2022 |
|:-----------------------------------------------------|:----|:--------------------------------|----------:|:----|:--|----------:|
| Accounts payable                                     |     | $                               |   806,004 |     | $ | 1,378,316 |
| Accrued employee costs                               |     |                                 | 1,213,054 |     |   | 1,216,242 |
| Accrued professional fees                            |     |                                 |    39,165 |     |   |   172,356 |
| Accrued research and development                     |     |                                 |   439,024 |     |   |   311,036 |
| Accrued board fees                                   |     |                                 |   117,750 |     |   |   116,000 |
| Delaware franchise taxes payable                     |     |                                 |    40,000 |     |   |   128,929 |
| Other accrued expenses                               |     |                                 |    17,330 |     |   |    29,968 |
| Total accounts payable and other current liabilities |     | $                               | 2,672,327 |     | $ | 3,352,847 |

NOTE 6: STOCK-BASED COMPENSATION

The Company has an equity incentive plan for grants to employees, officers, consultants, directors, and other service providers that was approved in 2021 (the “2021 Plan”). The maximum aggregate number of shares that may be issued pursuant to this 2021 Plan is 1,864,963shares (the “Pool”); provided, however that the Pool will